Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Genfit S.A.
Industry Sector: HealthTechnology
CEO: Pascal Prigent
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: 7.3
Exchange/Ticker 1: Euronext Paris:GNFT
Exchange/Ticker 2: NASDAQ:GNFT
Latest Market Cap: $178,939,548
BioCentury | Jul 17, 2024
Data Byte
FDA’s five NME approvals in June bring 1H24 total to 21
Ipsen’s Iqirvo, Geron’s Rytelo among June highlights
BioCentury | Jun 5, 2024
Data Byte
15 PDUFA dates on FDA’s roster in June
Upcoming decisions include HER3 ADC from Daiichi-Merck and full approval for Sarepta’s DMD gene therapy
BioCentury | Feb 12, 2024
Deals
Completing long comeback, liver play CymaBay agrees to $4.3B Gilead takeout
Gilead adds seladelpar, a PBC candidate now under priority review, to liver disease arsenal
BioCentury | Dec 7, 2023
Finance
Dec. 7 Quick Takes: Radiopharma play ARTbio bolsters team with $90M, Novartis vets
Plus: Regeneron’s bispecific heading to FDA and updates for Vanda, J&J, Merck, Ipsen, Genfit
BioCentury | Jul 1, 2023
Finance
June 30 Quick Takes: Genfit hits but falls short of competitor in primary biliary cholangitis
Plus: Novartis sells front-of-eye portfolio to B&L, and updates from argenx, Black Diamond, KangaBio and more
BioCentury | Dec 19, 2022
Product Development
Big gain for Madrigal as data are more than enough for NASH submission
Needing only one of two primary endpoints, THRB agonist hits both, tripling biotech’s value and lifting others in same disease area
BioCentury | Oct 5, 2022
Management Tracks
Owkin finds new CBO in Sanofi SVP
Plus CEO Séjourné moves to Aurobac and updates from Quantum, BioHaven and more
BioCentury | Sep 19, 2022
Deals
Genfit pads liver disease pipeline with Versantis takeout
Structured deal gives French biotech second asset for acute-on-chronic liver failure, plus more assets
BioCentury | Dec 18, 2021
Deals
Dec. 17 Quick Takes: Ipsen, Genfit advancing former NASH candidate in PBC
Plus: ALS play Amylyx seeking NASDAQ listing and updates from Novartis, Pfizer-BioNTech, IN8bio and more
BioCentury | Apr 23, 2021
Management Tracks
Genfit unveils a new CFO; plus Evotec, Autolus, Celyad, Lumos, Dewpoint and more
Metabolic and liver diseases company Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) hired Thomas Baetz as CFO. Baetz was director of healthcare at Dragon Financial Partners. Wolfgang Plischke will step down
Items per page:
1 - 10 of 161